KCT0008344尚未招募Unknown
Clinical Efficacy of rabeprazole in patients treated with dual antiplatelet agents including potent P2Y12 inhibitors after percutaneous coronary intervention for acute coronary syndrome
Yonsei University Yongin Severance Hospital0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 19(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1. Patients between 19 and 80 years of age.
- •2. Among patients diagnosed with acute coronary syndrome and who have undergone percutaneous coronary intervention(PCI), those who have agreed to participate in the study
- •3. Patients who need to take dual antiplatelet agents including potent P2Y12 inhibitor (Prasugrel, ticagreler) for more than 8 weeks after PCI.
- •4. A person who voluntarily agreed to participate in this clinical study.
- •5. A person who has agreed to use medically validated contraception methods (including medically impossible pregnancy conditions) during the clinical trial period.
排除标准
- •1) A person who cannot fill out a questionnaire on his/her own.
- •2) Patients who overreact to heparin, aspirin, prasugrel,ticagreler, or proton pump inhibitor.
- •3) A person who underwent surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, gastric acid secretion suppression, or gastric mucosal resection.
- •4) People who diagnosed with Zollinger-Ellison syndrome, inflammatory diseases (inflammatory bowel disease such as Crohn's disease or ulcerative colitis, pancreatitis, etc.).
- •5) Where upper gastrointestinal endoscopy is deemed inappropriate, or a person with gastrointestinal bleeding, active peptic ulcer, or malignant tumor.
- •6) A person who has a history of malignant tumors within 5 years. However, it may include those who have been diagnosed with complete remission of the tumor for more than 5 years without recurrence from the date of judgment and those who have passed more than 3 years without recurrence if the tumor is completely removed through endoscopic gastric mucosal resection or submucosal dissection.
- •7) Those who have taken proton pump inhibitors or H2RA, P-CAB-based drugs within two weeks, or those who have a history of gastrointestinal bleeding and must take proton pump inhibitors.
- •8) Patients with a Left ventricular systolic function of 30% or less on echocardiography.
- •9) Subjects with a life expectancy of less than 12 months.
- •10) A person who has shown clinically significant impairment in the liver, kidney, cardiovascular system, respiratory system, endocrine system, and central nervous system.
- •11) Pregnant women and lactating women or those who intend to conceive.
- •12) Patients with contraindication of administering aspirin, praschgrel, and ticagreler.
- •13) Patients with contraindication of administering proton pump inhibitors.
- •14) Patients who has clinical significant findings that are medically judged by the physician and deemed inappropriate for this study
研究者
相似试验
进行中（未招募）
1 期
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleEUCTR2016-001879-73-Outside-EU/EEAEisai Medical Research Inc.111
已完成
不适用
Efficacy and safety of two weeks rabeprazole treatment for gastric ulcers after endoscopic submucosal dissection (ESD).early gastric cancer or gastric adenomaJPRN-UMIN000000688The University of Tokyo, Department of Gastroenterology55
招募中
Unknown
Comparative study of efficacy of rabeprazole and lansoprazole for endoscopic submucosal dissection-induced ulcerNeoplasmsKCT0008599Kangwon National University Hospital100
未知
Unknown
Rabeprazole specific clinical experience investigation for the long-term combination therapy with low-dose aspiriGastric ulcer, Duodenal ulcerJPRN-jRCT1080222833Eisai Co., Ltd.1,400
尚未招募
不适用
Prevention of change of gastric Ph(acidity) and volume during laparoscopic cholecystectomy(removal of diseased gall bladder due to gall stone disease) by intravenous rabeprazole(Antacid)in patients during general anaesthesia to minimize risk of gastric aspiration and injury to lungsCTRI/2022/12/048045VCSGGMS and RI Srikot Srinagar Garhwal Uttarakhand